CDC Updates on Antibiotic Stewardship and Required Antimicrobial Use and Resistance Reporting - On Demand

U.S. Antibiotic Awareness Week (USAAW) is an annual observance that raises awareness of the threat of antibiotic resistance and the importance of appropriate antibiotic use. Antibiotic stewards may lack the knowledge of recently released CDC guidance to optimize antibiotic use and may be unaware of the requirements to meet the Antimicrobial Use and Resistance (AUR) Surveillance measure of the Centers for Medicare & Medicaid Services (CMS) Promoting Interoperability (PI) Program. Failure to fulfill any of the CMS PI Program required measures, including the AUR Surveillance measure, will result in a score of zero for the PI Program which may cause facilities to be subject to a downward payment adjustment. This presentation will describe CDC’s national antibiotic stewardship efforts including the soon to be released Core Elements of Antibiotic Stewardship for Health Departments. The presenters will also describe the calendar year 2024 requirements for reporting into NHSN to meet the AUR Surveillance measure within the CMS PI Program. Attendees will also learn about the AUR metrics available within NHSN.

Target Audience

Pharmacist

Pharmacy Technicians

Learning Objectives

Pharmacists learning objectives:

At the conclusion of this activity, pharmacists should be able to:

  1. Describe hospital Core Elements implementation and uptake.  
  2. Identify opportunities for hospital antibiotic stewardship programs to partner with Health Departments to optimize antibiotic prescribing in their state.  
  3. Outline the requirements for meeting the Antimicrobial Use and Resistance (AUR) Surveillance measure within the Centers for Medicare & Medicaid Services Promoting Interoperability Program.
  4. Summarize the metrics available to hospitals within the National Healthcare Safety Network (NHSN) AUR Module.

Pharmacy technician learning objectives:

At the conclusion of this activity, pharmacy technicians should be able to:

  1. Describe hospital Core Elements implementation and uptake.  
  2. Outline the requirements for meeting the Antimicrobial Use and Resistance (AUR) Surveillance measure within the Centers for Medicare & Medicaid Services Promoting Interoperability Program.

Additional Information

Course summary
Available credit: 
  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CE - Attendance
Course opens: 
11/17/2023
Course expires: 
11/16/2024
Rating: 
0

Faculty

Melinda Neuhauser, PharmD, MPH, FCCP, FASHP, FIDP
Pharmacist and Acute Care Lead, Office of Antibiotic Stewardship
Centers of Diseases Control and Prevention

Amy Webb, MPH, CHES
Senior Public Health Analyst
Lantana Consulting Group, INC
 

Planning committee

Gretchen Brummel, PharmD, BCPS 
Pharmacy Executive Director  
Vizient Center for Pharmacy Practice Excellence 
Vizient, Inc. 
 
Jackie Stokes, BBA 
Manager, Pharmacy Program  
Vizient, Inc. 

John Schoen, PharmD, BCPS
Senior Clinical Manager
Vizient, Inc.
 

Identification, Mitigation, and Disclosure of Relevant Financial Relationships

As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.

 

It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.

 

Disclosure of Financial Relationships:

Absence of Relevant Financial Relationships

Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.

No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.

 

Statement of Content Validity

Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.

 

FDA off-label/unapproved usage

Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.

Usage Disclosure: “Off-label/unapproved drug uses or products are mentioned within this activity.

Evidence-based Content: Low/absence of evidence-based topics are mentioned within this activity

Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.

Joint Accreditation Statement:

In support of improving patient care, Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Designation Statement(s):

PHARMACY

Vizient, Inc. designates this activity for a maximum of 1.00 ACPE credit hours.

UAN JA0006103-0000-23-338-H01-P

UAN JA0006103-0000-23-338-H01-T

 

OTHER

Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation.   Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re- certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.

Available Credit

  • 1.00 ACPE Pharmacist
  • 1.00 ACPE Pharmacy Technician
  • 1.00 General CE - Attendance
Please login or register to take this course.